ORIC Pharmaceuticals (FRA:4TZ) Total Assets: €377.80 Mil (As of Mar. 2026)


FRA:4TZ ORIC Pharmaceuticals Inc FRA:4TZ
32 GF Score
Price €9.13
! 3 Warning Signs
View Full Analysis

What is ORIC Pharmaceuticals Total Assets?

ORIC Pharmaceuticals FRA:4TZ -2.77% 32 Total Assets is €377.80 Mil as of Mar. 2026. GuruFocus rates FRA:4TZ with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

ORIC Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2026 was €377.80 Mil.

During the past 12 months, ORIC Pharmaceuticals's average Total Assets Growth Rate was 600.70% per year. During the past 3 years, the average Total Assets Growth Rate was 46.00% per year. During the past 5 years, the average Total Assets Growth Rate was 41.80% per year.

During the past 8 years, ORIC Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 146.90%. The lowest was -33.40%. And the median was 101.00%.

Total Assets is connected with ROA %. ORIC Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2026 was -34.04%. Total Assets is also linked to Revenue through Asset Turnover. ORIC Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

ORIC Pharmaceuticals  (FRA:4TZ) Total Assets Explanation

Total Assets is connected with ROA %.

ORIC Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-123.752/( (349.192+377.799)/ 2 )
=-123.752/363.4955
=-34.04 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

ORIC Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0/( (349.192+377.799)/ 2 )
=0/363.4955
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

ORIC Pharmaceuticals Total Assets Related Terms

ORIC Pharmaceuticals Total Assets Historical Data

* Premium members only.

The historical data trend for ORIC Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ORIC Pharmaceuticals Total Assets Chart

ORIC Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial 264.30 233.34 231.09 261.81 349.19

ORIC Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 224.64 300.73 367.38 349.19 377.80
FRA:4TZ
32GF Score
ORIC Pharmaceuticals Inc FRA:4TZ
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ORIC Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

ORIC Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=328.245+20.947
=349.19

ORIC Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=359.457+18.342
=377.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of €377.80 Mil mean?
ORIC Pharmaceuticals (FRA:4TZ) has a Total Assets of €377.80 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on ORIC Pharmaceuticals and its competitors.
Is ORIC Pharmaceuticals' Total Assets too high?
ORIC Pharmaceuticals' current Total Assets is €377.80 Mil. Overall, ORIC Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does ORIC Pharmaceuticals' Total Assets compare to DRTS and OLMA?
ORIC Pharmaceuticals' Total Assets of €377.80 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on ORIC Pharmaceuticals and its competitors. ORIC Pharmaceuticals's current Total Assets is €377.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ORIC Pharmaceuticals stock overvalued right now?
ORIC Pharmaceuticals (FRA:4TZ) has a current Total Assets of €377.80 Mil. The current Total Assets is €377.80 Mil. ORIC Pharmaceuticals' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For ORIC Pharmaceuticals (FRA:4TZ), the current Total Assets is €377.80 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ORIC Pharmaceuticals Business Description

Other Exchanges ORIC:USA
Address 240 E. Grand Avenue, 2nd Floor, South San Francisco, CA, USA, 94080
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
32GF Score

Get the complete analysis for FRA:4TZ

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.13
Price